Tenderwize
Zurück zur Suche

Open-house framework agreement for Aripiprazole depot injection suspension

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Jul 03, 2027 · 309 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Aripiprazol in der Darreichungsform Depot-Injektionssuspension, ATC N05AX12 (Kopie)

56/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

56 / 100

Komplexität

48 / 100

Risikofaktoren

Contract documents must be submitted through the DTVP communication area, not the offer area; wrong channel could jeopa...

The last possible date for contract conclusion is 2027-07-03, and monthly start dates depend on the 3rd of the month cu...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Aug 2027
  • Non-exclusive pharmaceutical rebate agreements for Aripiprazole depot injection suspension (ATC N05AX12).
  • Framework/open-house arrangement under § 130a(8) SGB V, with identical, non-individually negotiable contract terms.
Vollständige Zusammenfassung anzeigen

Open-house supply arrangement for Aripiprazole depot injection suspension (ATC N05AX12) in Germany, led by AOK Bayern. The model is non-exclusive and open to all pharmaceutical companies that meet the stated self-declared reliability requirement. No contract value is provided. Submission is via DTVP or by signed paper originals; the deadline for contracts starting on the next month begins on the 3rd of the previous month, and the final contract conclusion date is 2027-07-03.

Risiken

Contract documents must be submitted through the DTVP communication area, not the offer area; wrong channel could jeopa...

The last possible date for contract conclusion is 2027-07-03, and monthly start dates depend on the 3rd of the month cu...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • The signatory's authority must be evidenced by the commercial register excerpt; otherwise a power of attorney is required.

Eligibility

  • Only pharmaceutical companies are eligible as potential contractual partners.

Administrative

  • Submit the completed and signed contract, completed and signed Annex 'Festlegung der vertragsgegenständlichen Arzneimittel', and completed and signed self-declaration on...

Auftraggeber

Ort

München, DEU

Website

www.aok.de

Auftraggeberprofil

Profil öffnen

Kennung

DE811695320

Tätigkeit

Health

Lose (1)

LOT-0001

Open-house framework agreement for Aripiprazole depot injection suspension

Lot 1 covers non-exclusive open-house rebate agreements for Aripiprazole in depot injection suspension form (ATC N05AX12). The notice states this is an open-house model, not a competitive open procedure, and contracts are offered on identical, non-negotiable terms to qualifying pharmaceutical companies. The lot is sourced from structured data and XML notice.

SuppliesFrameworkEU fundedElectronic submission

Ort

DE212, Germany

Dauer

Aug 2025 - Aug 2027

Kategorie

Pharmaceutical products

Frist

Deadline Jul 03, 2027

Vergabedetails

Veröffentlichungsdatum
24 Jul 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
488809-2025

Dokumente (2)

Vergabedokument 1Einreichungsportal 1

Ähnliche Ausschreibungen

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30